London, UK – 8 October, 2026 – Tate & Lyle PLC (Tate & Lyle), a global leader in ingredient solutions for healthier food and beverages, and BioHarvest Sciences Inc. (NASDAQ: BHST) (BioHarvest), today announced an important milestone in their next-generation sweetener development programme.
The programme has demonstrated that BioHarvest’s Botanical Synthesis™ platform is capable of producing the targeted next-generation sweetening solution. The achievement marks continued positive progress in the collaboration, with both companies encouraged by the results achieved to date.
Development activities continue to advance in line with expectations, providing further evidence of the promising capabilities of BioHarvest’s Botanical Synthesis™ platform and its potential to support innovative approaches to ingredient development.
Food and beverage manufacturers continue to seek a broader range of sweetening solutions that can support sugar and calorie reduction while delivering the taste and functionality consumers expect. New approaches to ingredient development have the potential to expand the tools available to manufacturers as they respond to different formulation needs across food and beverage categories.
BioHarvest’s Botanical Synthesis™ platform represents an innovative approach to ingredient development and production. It has the potential to support more sustainable access to valuable plant-derived ingredients by reducing dependence on traditional agricultural production methods. The approach could also improve consistency and supply reliability, while reducing some of the time, labour and natural resources required to produce certain ingredients.
The milestone builds on the expanded collaboration announced by Tate & Lyle and BioHarvest in May 2026 and reflects the continued advancement of the companies’ work together on sweetener innovation.
Susanna Palatucci, Vice President, Commercial Innovation and Strategy at Tate & Lyle, said: “Different food and beverage categories demand different balances of taste, nutrition, cost and labelling, which is why building a broader toolbox of solutions matters. This milestone further bolsters the potential of BioHarvest’s Botanical Synthesis™ platform and the role new approaches to ingredient development could play in helping us meet those varied customer needs across our portfolio.
“What makes technologies like this particularly interesting is their potential to open up new ways of accessing valuable ingredients, while also considering consistency, supply reliability and the responsible use of natural resources. We’re encouraged by the progress of the programme and what it could add to our science-led approach to sweetener innovation.”
Dr Zaki Rakib, Chief Executive Officer and Executive Chairman of BioHarvest Sciences, said: “The value of this collaboration goes beyond a single development programme. It is about exploring how Botanical Synthesis™ can open up new approaches to ingredient innovation, particularly where traditional production methods can be complex or resource-intensive.
“Working with Tate & Lyle brings together our platform with deep expertise in sweetening, formulation and customer needs. That combination is helping us build a clearer picture of where Botanical Synthesis™ can make a meaningful contribution to the future of sweetener development.”
ENDS
For media enquiries, contact: [email protected]
About BioHarvest Sciences Inc:
BioHarvest Sciences Inc. (NASDAQ: BHST) (TASE: BHST) (FSE: 8MV0) is a Botanical Synthesis company leveraging its proprietary technology platform to develop and manufacture plant-based compositions without growing the underlying plant. Through Botanical Synthesis, BioHarvest produces consistent, full-spectrum plant compound compositions designed for commercial use across consumer and partner applications, advancing BioHarvest’s mission to provide natural wellness at scale.
The Company is increasingly focused on applying its Botanical Synthesis capabilities as a Contract Development and Manufacturing Organization (CDMO), partnering with customers to develop, scale, and manufacture valuable plant-based compositions across multiple industries. BioHarvest combines plant-cell biology, process development, and scaled manufacturing to provide partners with a path from plant cells to commercially viable compositions.
BioHarvest also owns proprietary assets developed through its Botanical Synthesis platform, including VINIA®, its first consumer product from Botanical Synthesis and commercially established red-grape cell composition. These proprietary assets provide BioHarvest with additional opportunities for value creation while demonstrating the commercial capabilities of its technology platform.
To learn more, please visit .
